Home » Stocks » GTBP

GT Biopharma, Inc (GTBP)

Stock Price: $16.55 USD 0.46 (2.86%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $16.80 +0.25 (1.51%) May 7, 7:59 PM
Market Cap 469.92M
Revenue (ttm) n/a
Net Income (ttm) -28.30M
Shares Out 4.39M
EPS (ttm) -6.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $16.55
Previous Close $16.09
Change ($) 0.46
Change (%) 2.86%
Day's Open 16.03
Day's Range 15.49 - 16.75
Day's Volume 648,849
52-Week Range 3.90 - 17.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Penny stocks are hot right now and these former low-priced names are reaching for new highs this month. The post Former Penny Stocks To Watch Making New Highs In May 2021 appeared first on Penny Stocks ...

Other stocks mentioned: ISNS, OCGN, RHE
6 days ago - PennyStocks

In the latest trading session, OXIS International Inc. (GTBP) closed at $11.74, marking a +0.34% move from the previous day.

1 week ago - Zacks Investment Research

These biotech penny stocks have begun turning heads in April 2021 The post 3 Penny Stocks To Watch As Biotech Surges In April 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | Pe...

Other stocks mentioned: ASXC, ZOM
1 week ago - PennyStocks

BEVERLY HILLS, Calif., April 26, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:… The post GT Biopharma Announces the Appointments of Gregory Berk, M.D.

1 week ago - PennyStocks

BEVERLY HILLS, Calif., April 26, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's pro...

1 week ago - PRNewsWire

In the latest trading session, OXIS International Inc. (GTBP) closed at $9.64, marking a +0.63% move from the previous day.

2 weeks ago - Zacks Investment Research

List Of Penny Stocks To Watch Right Now The post Hot Penny Stocks To Watch In April 2021 If Biotech Is A Focus appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other stocks mentioned: AVGR, SENS
2 weeks ago - PennyStocks

BEVERLY HILLS, Calif., April 19, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's pro...

2 weeks ago - PRNewsWire

BEVERLY HILLS, Calif., April 12, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's pro...

3 weeks ago - PRNewsWire

BEVERLY HILLS, Calif., April 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's prop...

1 month ago - PRNewsWire

BEVERLY HILLS, Calif., March 29, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's pro...

1 month ago - PRNewsWire

GT Biopharma Inc (NASDAQ: GTBP) has reported updated interim data from Phase 1/2 clinical trial, evaluating the Company's lead candidate, GTB-3550, in high-risk myelodysplastic syndromes (MDS) and refra...

1 month ago - Benzinga

BEVERLY HILLS, Calif., March 17, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's prop...

1 month ago - PRNewsWire

BEVERLY HILLS, Calif., March 10, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage biopharmaceutical company focused on the development and commercialization of disruptive, target-...

1 month ago - PRNewsWire

BEVERLY HILLS, Calif.--(BUSINESS WIRE)--GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on the development and commercialization of its disruptive, target-directed ...

2 months ago - Business Wire

BEVERLY HILLS, Calif.--(BUSINESS WIRE)--GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) ...

2 months ago - Business Wire

BEVERLY HILLS, Calif., Jan. 19, 2021 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell enga...

3 months ago - PRNewsWire

BEVERLY HILLS, Calif., Dec. 28, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell enga...

4 months ago - PRNewsWire

BEVERLY HILLS, Calif, Dec. 21, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engag...

4 months ago - PRNewsWire

BEVERLY HILLS, Calif., Dec. 17, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) a company focused on developing innovative therapeutic treatments based on its proprietary NK cell engager...

4 months ago - PRNewsWire

BEVERLY HILLS, Calif., Dec. 14, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell enga...

4 months ago - PRNewsWire

With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 Biotech Pe...

Other stocks mentioned: CANF, FPRX, IFRX, TNXP, VTVT, VXRT
5 months ago - InvestorPlace

GT Biopharma (GTBP) news for Tuesday about it working on a possible treatment for the coronavirus from China has GTBP stock heading higher.

1 year ago - InvestorPlace

About GTBP

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops various immuno-oncology product candidates, including GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced sy... [Read more...]

Industry
Biotechnology
Founded
1965
CEO
Anthony Cataldo
Employees
3
Stock Exchange
NASDAQ
Ticker Symbol
GTBP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for GT Biopharma is 23.00, which is an increase of 38.97% from the latest price.

Price Target
$23.00
(38.97% upside)